St. Jude Medical Announces Publication of 20-Year Durability Data on Tissue Heart Valve
October 28, 2008 – A study on the St. Jude Medical Biocor Stented Tissue Valve, which appears in the October issue of the cardiac journal The Annals of Thoracic Surgery, evaluated the 20-year durability of the Biocor porcine valve in the aortic position and found the valve provided excellent long-term durability as a replacement for the aortic valve in patients 65 years and older.
According to the study, over the 20-year follow-up period, the Biocor valve was found to perform well on key measures of long-term performance including freedom from re-operation due to structural valve deterioration (the rate at which patients remain free from another operation related to degeneration that could affect the valve’s proper functioning).
The study found that the Biocor valve’s rate of freedom from re-operation for structural valve deterioration was 86.5 percent at 20 years compared to data reported for other tissue valves, which have ranged from 52.9 to 67 percent (in 17 to 20 year follow-up studies).
“The excellent long-term durability found in the study confirms the results of other, earlier Biocor studies and shows that the Biocor valve has lower structural valve deterioration and re-operation rates than most other tissue valves that have been followed long-term,” said the study’s lead investigator, Walter Eichinger, M.D., of the German Heart Center in Munich, Germany.
The long-term performance of tissue heart valves is of growing importance as physicians seek solutions for younger patients with heart disease while seeking to avoid the need for re-operation. Physicians increasingly consider implanting tissue valves as studies demonstrate improved durability when compared to prior generation tissue valve designs.
While the excellent long-term performance of mechanical valves is well documented, patients who receive a mechanical valve must take anticoagulant (anti-clotting) medications for life. Patients who receive a tissue valve are typically not required to take anticoagulants as the risk of blood clots is less. Current European and U.S. clinical guidelines recommend tissue valves for patients 65 or older.
“Twenty-year studies such as this are of special importance in helping doctors advise patients concerning their individual risk after valve replacement,” said Dr. Eichinger.
The Biocor valve study, which was sponsored by St. Jude Medical, consecutively enrolled 455 patients who received a St. Jude Medical Biocor tissue valve to replace their aortic valve at the German Heart Center Munich from Jan. 1985 through Dec. 1996. Follow-up occurred between 2003 and 2006. Following standardized follow-up methods, researchers received responses to a questionnaire or reviewed the medical records of 99.6 percent of the enrolled patients. The study population included equal numbers of patients younger and older than its mean age of 72.5 years.
For more information: www.sjm.com
More like this
- St. Jude Medical Announces Publication of 20-year Durability in Aortic, Mitral Stented Tissue Valves
- St. Jude Medical’s Epic Stented Tissue Valve with Anti-Calcification Technology Receives FDA Approval
- St. Jude Medical Announces First Enrollment in Anti-Clotting Study
- FDA Clears Trifecta Stented Tissue Aortic Valve
- St. Jude Medical Launches New Trifecta Heart Valve in Japan